TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts

Journal of Immunology

Volumn 176, Issue 3, 2006, Pages 1561-1570

  Thornley, Thomas B ^a   Brehm, Michael A ^a   Markees, Thomas G ^a   Shultz, Leonard D ^b   Mordes, John P ^a   Welsh, Raymond M ^a   Rossini, Aldo A ^a   Greiner, Dale L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CD8 ANTIGEN; CD8ALPHA ANTIGEN; HERMES ANTIGEN; IMMUNOLOGIC AGENT; INTERLEUKIN 12 RECEPTOR; KI 67 ANTIGEN; LIPOPOLYSACCHARIDE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; CROSS REACTION; DONOR; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN ALLOGRAFT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

EID: 31144479123     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.3.1561     Document Type: Article

References (70)

1. Rickels, M. R., M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff. 2005. β-cell function following human islet transplantation for type 1 diabetes. Diabetes 54: 100-106.
2. Street, C. N., J. R. T. Lakey, A. M. J. Shapiro, S. Imes, R. V. Rajotte, E. A. Ryan, J. G. Lyon, T. Kin, J. Avila, T. Tsujimura, and G. S. Korbutt. 2004. Islet graft assessment in the Edmonton protocol-implications for predicting long-term clinical outcome. Diabetes 53: 3107-3114.
3. Shapiro, A. M. J., J. R. T. Lakey, E. A. Ryan, G. S. Korbutt, E. Toth, G. L. Warnock, N. M. Kneteman, and R. V. Rajotte. 2000. Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343: 230-238.
4. Ryan, E. A., J. R. T. Lakey, B. W. Paty, S. Imes, G. S. Korbutt, N. M. Kneteman, D. Bigam, R. V. Rajotte, and A. M. J. Shapiro. 2002. Successful islet transplantation-continued insulin reserve provides long-term glycemic control. Diabetes 51: 2148-2157.
5. Teraoka, S., T. Kawai, Y. Yamaguchi, S. Fujita, T. Tojinbara, T. Nakajima, T. Hayashi, Y. Nakagawa, H. Fujikawa, H. Honda, et al. 1990. Mechanism of the preventive effect of aminobenzoic acid salt on pancreatic β cell toxicity by cyclosporin. Transplant. Proc. 22: 863-866.
6. Newstead, C. G. 1998. Assessment of risk of cancer after renal transplantation. Lancet 351: 610-611.
7. Parker, D. C., D. L. Greiner, N. E. Phillips, M. C. Appel, A. W. Steele, F. H. Durie, R. J. Noelle, J. P. Mordes, and A. A. Rossini. 1995. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 92: 9560-9564.
8. Markees, T. G., N. E. Phillips, R. J. Noelle, L. D. Shultz, J. P. Mordes, D. L. Greiner, and A. A. Rossini. 1997. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation 64: 329-335.
9. Elster, E. A., H. Xu, D. K. Tadaki, S. Montgomery, L. C. Burkly, J. D. Berning, R. E. Baumgartner, F. Cruzata, R. Marx, D. M. Harlan, and A. D. Kirk. 2001. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation 72: 1473-1478.
10. Kenyon, N. S., L. A. Fernandez, R. Lehmann, M. Masetti, A. Ranuncoli, M. Chatzipetrou, G. Iaria, D. M. Man, J. L. Wagner, P. Ruiz, et al. 1999. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 48: 1473-1481.
11. Kenyon, N. S., M. Chatzipetrou, M. Masetti, A. Ranuncoli, M. Oliveira, J. L. Wagner, A. D. Kirk, D. M. Harlan, L. C. Burkly, and C. Ricordi. 1999. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc. Natl. Acad. Sci. USA 96: 8132-8137.
12. Preston, E. H., H. Xu, K. K. Dhanireddy, J. P. Pearl, F. V. Leopardi, M. F. Starost, D. A. Hale, and A. D. Kirk. 2005. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am. J. Transplant. 5: 1032-1041.
13. Larsen, C. P., and T. C. Pearson. 1997. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr. Opin. Immunol. 9: 641-647.
14. Foy, T. M., A. Aruffo, J. Bajorath, J. E. Buhlmann, and R. J. Noelle. 1996. Immune regulation by CD40 and its ligand gp39. Ann. Rev. Immunol. 14: 591-617.
15. + T cells and prolonged graft survival in a CTLA4-dependent manner. J. Immunol. 164: 512-521.
16. Li, Y., X. C. Li, X. X. Zheng, A. D. Wells, L. A. Turka, and T. B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5: 1298-1302.
17. Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5: 1303-1307.
18. + T cells play a critical role in costimulation blockade-resistant allograft rejection. J. Clin. Invest. 104: 1715-1722.
19. + T cell deletion induced by donor-specific transfusion and anti-CD154 monoclonal antibody. Curr. Surg. 57: 505-506.
20. Welsh, R. M., T. G. Markees, B. A. Woda, K. A. Daniels, M. A. Brehm, J. P. Mordes, D. L. Greiner, and A. A. Rossini. 2000. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J. Virol. 74: 2210-2218.
21. Forman, D., R. M. Welsh, T. G. Markees, B. A. Woda, J. P. Mordes, A. A. Rossini, and D. L. Greiner. 2002. Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms. J. Immunol. 168: 6047-6056.
22. Yang, H. Y., P. L. Dundon, S. R. Nahill, and R. M. Welsh. 1989. Virus-induced polyclonal cytotoxic T lymphocyte stimulation. J. Immunol. 142: 1710-1718.
23. Nahill, S. R., and R. M. Welsh. 1993. High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response. J. Exp. Med. 177: 317-327.
24. Brehm, M. A., T. G. Markees, K. A. Daniels, D. L. Greiner, A. A. Rossini, and R. M. Welsh. 2003. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J. Immunol. 170: 4077-4086.
25. Adams, A. B., M. A. Williams, T. R. Jones, N. Shirasugi, M. M. Durham, S. M. Kaech, E. J. Wherry, T. Onami, J. G. Lanier, K. E. Kokko, et al. 2003. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 111: 1887-1895.
26. Boehme, K. W., and T. Compton. 2004. Innate sensing of viruses by Toll-like receptors. J. Virol. 78: 7867-7873.
27. Devendra, D., and G. S. Eisenbarth. 2004. Interferon α-a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin. Immunol. 111: 225-233.
28. Matsumoto, M., K. Funami, H. Oshiumi, and T. Seya. 2004. Toll-like receptor 3: a link between Toll-like receptor, interferon and viruses. Microbiol. Immunol. 48: 147-154.
29. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Ann. Rev. Immunol. 21: 335-376.
30. Kurt-Jones, E. A., L. Popova, L. Kwinn, L. M. Haynes, L. P. Jones, R. A. Tripp, E. E. Walsh, M. W. Freeman, D. T. Golenbock, L. J. Anderson, and R. W. Finberg. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1: 398-401.
31. Bieback, K., E. Lien, I. M. Klagge, E. Avota, J. Schneider-Schaulies, W. P. Duprex, H. Wagner, C. J. Kirschning, V. Ter Meulen and S. Schneider-Schaulies. 2002. Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling. J. Virol. 76: 8729-8736.
32. Diebold, S. S., T. Kaisho, H. Hemmi, S. Akira, and C. R. E. Sousa. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
33. Zhou, S., E. A. Kurt-Jones, L. Mandell, A. Cerny, M. Chan, D. T. Golenbock, and R. W. Finberg. 2005. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 35: 822-830.
34. Tabeta, K., P. Georgel, E. Janssen, X. Du, K. Hoebe, K. Crozat, S. Mudd, L. Shamel, S. Sovath, J. Goode, et al. 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 101: 3516-3521.
35. Goldstein, D. R., B. M. Tesar, S. Akira, and F. G. Lakkis. 2003. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J. Clin. Invest. 111: 1571-1578.
36. Kaisho, T., O. Takeuchi, T. Kawai, K. Hoshino, and S. Akira. 2001. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J. Immunol. 166: 5688-5694.
37. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
38. Schonrich, G., U. Kalinke, F. Momburg, M. Malissen, A. M. Schmitt-Verhulst, B. Malissen, G. J. Hämmerling, and B. Arnold. 1991. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 65: 293-304.
39. Iwakoshi, N. N., T. G. Markees, N. A. Turgeon, T. Thornley, A. Cuthbert, J. H. Leif, N. E. Phillips, J. P. Mordes, D. L. Greiner, and A. A. Rossini. 2001. Skin allograft maintenance in a new synchimeric model system of tolerance. J. Immunol. 167: 6623-6630.
40. + T cells, interferon-γ, and CTLA4. J. Clin. Invest. 101: 2446-2455.
41. Selin, L. K., S. R. Nahill, and R. M. Welsh. 1994. Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses. J. Exp. Med. 179: 1933-1943.
42. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J. Immunol. 165: 618-622.
43. Hua, C., C. Boyer, M. Buferne, and A. M. Schmitt-Verhulst. 1986. Monoclonal antibodies against an H-2Kb-specific cytotoxic T cell clone detect several clone-specific molecules. J. Immunol 136: 1937-1944.
44. Selin, L. K., M. Y. Lin, K. A. Kraemer, D. M. Pardoll, J. P. Schneck, S. M. Varga, P. A. Santolucito, A. K. Pinto, and R. M. Welsh. 1999. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 11: 733-742.
45. + cell subsets and different mechanisms. Transplantation 78: 660-667.
46. Markees, T. G., T. Pearson, A. Cuthbert, A. L. Pearson, L. D. Shultz, J. Leif, N. E. Phillips, J. P. Mordes, D. L. Greiner, and A. A. Rossini. 2004. Evaluation of donor-specific transfusion sources: unique failure of bone marrow cells to induce prolonged skin allograft survival with anti-CD154 monoclonal antibody. Transplantation 78: 1601-1608.
47. Curtsinger, J. M., D. C. Lins, and M. F. Mescher. 2003. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197: 1141-1151.
48. Kim, E. Y., and H. S. Teh. 2001. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J. Immunol 167: 6812-6820.
49. Kim, E. Y., and H. S. Teh. 2004. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J. Immunol. 173: 4500-4509.
50. Aspalter, R. M., M. M. Eibl, and H. M. Wolf. 2003. Regulation of TCR-mediated T cell activation by TNF-RII. J. Leukocyte Biol. 74: 572-582.
51. Shrikant, P., and M. F. Mescher. 2002. Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J. Immunol. 169: 1753-1759.
52. Kim, E. Y., and H. S. Teh. 2001. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J. Immunol 167: 6812-6820.
53. Schulz, O., S. S. Diebold, M. Chen, T. I. Naslund, M. A. Nolle, L. Alexopoulou, Y. T. Azuma, R. A. Flavell, P. Liljestrom, and C. Reis e Sousa. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
54. Akira, S., and K. Takeda. 2004. Functions of Toll-like receptors: lessons from KO mice. C. R. Biol. 327: 581-589.
55. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
56. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263.
57. Tesar, B. M., J. Zhang, Q. Li, and D. R. Goldstein. 2004. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am. J. Transplant. 4: 1429-1439.
58. Karin, M., and E. Gallagher. 2005. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57: 283-295.
59. Adam-Klages, S., D. Adam, O. Janssen, and D. Kabelitz. 2005. Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity. Immunol. Res. 33: 149-166.
60. Sabapathy, K., Y. Hu, T. Kallunki, M. Schreiber, J. P. David, W. Jochum, E. F. Wagner, and M. Karin. 1999. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 9: 116-125.
61. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291: 2413-2417.
62. Reinhardt, R. L., A. Khoruts, R. Merica, T. Zell, and M. K. Jenkins, 2001. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410: 101-105.
63. + T cells by the normal liver. J. Immunol. 163: 3202-3210.
64. McNally, J. M., C. C. Zarozinski, M. Y. Lin, M. A. Brehm, H. D. Chen, and R. M. Welsh. 2001. Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J. Virol. 75: 5965-5976.
65. Monk, N. J., R. E. O. Hargreaves, J. E. Marsh, C. A. Farrar, S. H. Sacks, M. Millrain, E. Simpson, J. Dyson, and S. Jurcevic. 2003. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat. Med. 9: 1275-1280.
66. Hochrein, H., K. Shortman, D. Vremec, B. Scott, P. Hertzog, and M. O'Keeffe. 2001. Differential production of IL-12, IFN-α, and IFN-γ by mouse dendritic cell subsets. J. Immunol. 166: 5448-5455.
67. + T lymphocyte-deficient mice. Transplantation 55: 718-722.
68. Curtsinger, J. M., J. O. Valenzuela, P. Agarwal, D. Lins, and M. F. Mescher. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174: 4465-4469.
69. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413: 732-738.
70. Edelmann, K. H., S. Richardson-Burns, L. Alexopoulou, K. L. Tyler, R. A. Flavell, and M. B. A. Oldstone. 2004. Does Toll-like receptor 3 play a biological role in virus infections? Virology 322: 231-238.